Apogee Therapeutics Inc SEC Filings

Apogee Therapeutics (APGE) is a clinical-stage biotech focused on inflammatory and immunology targets. The company reported a six-month net loss of $121.4 million and an accumulated deficit of $427.4 million. Research and development expense rose sharply to $102.1 million for the six months ended June 30, 2025 (compared with $61.9 million a year earlier), while general and administrative was $34.2 million.

The balance sheet shows $124.2 million of cash and cash equivalents, $381.2 million of current marketable securities and $115.8 million of long-term marketable securities, totaling roughly $621.2 million of liquidity. Operating cash used was $110.5 million in the first six months of 2025, and management states these resources should fund operations for at least the next 12 months. The company continues to advance multiple programs (IL-13, IL-4Rα, OX40L, TSLP) under licenses from Paragon and maintains manufacturing and supply agreements with WuXi Biologics and Samsung Biologics, with related milestone and service payments disclosed.

Apogee Therapeutics, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this Current Report as Exhibit 99.1, and a Cover Page Interactive Data File is provided as Exhibit 104.

The filing states that the exhibit furnished under Item 2.02 is not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. The registrant is Apogee Therapeutics, Inc., incorporated in Delaware, trading on the Nasdaq Global Market under the symbol APGE.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported a sale of 2,725 shares of Apogee common stock on 08/06/2025 at a reported price of $37.78 per share. The transaction is recorded on a Form 4 and was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024, a plan described in the filing as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The filing shows that following the reported sale Mr. Dambkowski beneficially owned 236,273 shares, held directly. No derivative transactions are reported on this Form 4 and the document is limited to the single non-derivative sale and the related ownership position.

Apogee Therapeutics (APGE) filed an 8-K to disclose positive 16-week data from Part A of its Phase 2 APEX trial evaluating APG777, an anti-IL-13 antibody, in moderate-to-severe atopic dermatitis (AD). The randomized, placebo-controlled study (n = 123; 2:1 randomization) met its primary endpoint, delivering a 71.0% mean EASI score reduction versus 33.8% for placebo. Key secondary endpoints also favored APG777, with EASI-75 achieved by 66.9% of treated patients (24.6% placebo) and EASI-90 by 33.9% (14.7% placebo). Exposure-response analyses showed up to 89.5% EASI-75 in the highest drug-exposure quartile.

Safety appeared benign: TEAEs occurred in 56.1% of treated subjects versus 63.4% placebo, serious TEAEs were 1.2% vs 2.4%, and no injection-site reactions were reported. Common events—non-infective conjunctivitis, URTI, nasopharyngitis—were comparable or lower than placebo.

Next steps: Part B (≈280 pts, four-arm dose optimisation) is enrolling with 16-week data expected mid-2026, enabling a planned Phase 3 start in 2026. Maintenance data (3-/6-month dosing) from Part A are due 1H 2026. A separate Phase 1b head-to-head trial of APG279 versus Dupixent has begun, with readout 2H 2026.

The company will host a conference call on 7 July 2025 at 8:00 a.m. ET to review results. Exhibits 99.1 and 99.2 contain the full press release and deck; they are furnished, not filed.